Close menu




November 14th, 2024 | 07:45 CET

Daimler Truck, dynaCERT, Bayer AG: Contrasts in Q3: Established companies under pressure, newcomers with breakthroughs

  • Hydrogen
  • greenhydrogen
  • Trucks
  • Agriculture
  • Pharma
Photo credits: pixabay.com

Established DAX corporations such as Bayer AG and Daimler Truck, a Mercedes-Benz Group company, are facing a headwind in the third quarter of 2024. However, the Canadian cleantech specialist dynaCERT is on the verge of its commercial breakthrough. The Leverkusen-based Bayer Group has to revise its forecast downwards. The agriculture business, in particular, is a cause for concern, while the pharmaceuticals division is scoring points with new drugs. At Daimler Truck, strong business in North America is stabilizing the balance sheet, while business in Europe is under pressure. dynaCERT, on the other hand, has received the valuable Verra certification for its hydrogen technology for diesel optimization after twenty years of development work. Investors finally have a viable hydrogen use case for logistics.

time to read: 4 minutes | Author: Juliane Zielonka
ISIN: BAYER AG NA O.N. | DE000BAY0017 , DYNACERT INC. | CA26780A1084 , Daimler Truck Holding AG | DE000DTR0013

Table of contents:


    Sebastian-Justus Schmidt, CEO and Founder, Enapter AG
    "[...] Why should a modular electrolyzer cost more than a motorcycle? [...]" Sebastian-Justus Schmidt, CEO and Founder, Enapter AG

    Full interview

     

    Daimler Truck: Struggling with challenging market environment in Europe

    Daimler Truck, the world's largest commercial vehicle manufacturer and part of the Mercedes-Benz Group, recorded a 12% decline in operating profit to EUR 1.19 billion in the third quarter of 2024. While business in North America remains stable, with an increase of 2% to EUR 725 million, profit in the Mercedes-Benz brand's European business fell by 47% to EUR 283 million. One might suspect that Brussels' regulations are playing a role in this decline.

    CFO Eva Scherer sees no signs of an imminent recovery in the German economy. Political uncertainty following the collapse of the federal government could further exacerbate the situation. Germany is particularly important for Daimler Truck, as its market share here is twice as high as in the rest of Europe.

    The Company is flexible with regard to possible US punitive tariffs under a future Trump administration. "We can produce every truck and bus model in both the US and Mexico," emphasizes Scherer. There is no one-sided dependence on Mexican production sites.

    Despite the challenging environment, Daimler Truck confirmed its annual forecast. The stock reacted positively and gained 3.8%. The group had already revised its expectations downwards in July and announced short-time work for parts of its German workforce in August.

    dynaCERT: Breakthrough in CO₂ certification opens up a billion-dollar market

    After two decades of intensive research and development, the Canadian technology group dynaCERT is on the verge of a historic breakthrough in the global CO₂ reduction market. Since its founding in 2004, the Company has invested more than CAD 100 million in the development of its patented HydraGEN technology. On October 4, 2024, dynaCERT received the long-awaited Verra certification, which opens up completely new perspectives for reducing emissions from diesel engines. kapitalerhoehungen.de/interviews/dynacert-inc-president-bernd-krueper-ueber-wasserstoff-flottenbetreiber-esg-dieselmotoren-und-aktienkurs

    The technology produces small quantities of hydrogen and oxygen from distilled water, which are fed to the engine via the air supply. This significantly improves the combustion of the diesel fuel. Tests show a reduction of nitrogen oxides by up to 88% and CO₂ emissions by 6 to 19%. Fuel consumption decreases by an average of 10%.

    For further expansion, dynaCERT has strengthened its management team with the German industry manager Bernd Krüper. The former CEO of the Hatz Group linkedin.com/in/bernd-kr%C3%BCper-b26b4559 will market the certified technology internationally. With its 15% stake in electrolyser specialist Cipher Neutron, the Company has also positioned itself technologically for the future.

    With Verra certification, customers can now use an environmental solution for about CAD 6,000 per vehicle, which pays for itself in less than six months through fuel savings and the sale of CO₂ certificates. dynaCERT plans to sell around 10,000 units in 2025. The production capacity at the partially automated plant in Toronto is 6,000 units per month.

    Bayer AG: Facing headwinds in all sectors

    Bayer is facing significant challenges in the third quarter of 2024. The Leverkusen-based group recorded a 4% decline in revenue to EUR 10.0 billion. Operating profit before special items fell by more than a quarter to EUR 1.3 billion.

    The agriculture division is a particular cause for concern. In Latin America, business is suffering from challenging market conditions. Demand for the weedkiller glyphosate has stabilized at a lower level, leading to a 19% decline in sales of these products bayer.com/sites/default/files/2024-11/q3-2024-2024-11-12-presentation-charts-en.pdf.

    There are rays of hope in the pharmaceuticals division. The new drugs Nubeqa® for prostate cancer and Kerendia® for kidney patients are developing well. However, increasing competitive pressure from generic products for the important anticoagulant Xarelto® is causing trouble for the Company.

    Given this development, Bayer has to correct its forecast for the year as a whole downwards. Instead of a slight growth, the Company now expects a decline in sales of 1 to 3%. Bayer also expects a sharper decline in operating profit than previously forecast.

    Meanwhile, the new CEO, Bill Anderson, is pushing ahead with the reorganization of the Company. By the end of the year, over 1,000 customer-focused teams are expected to bring the new organizational structure to life. In doing so, Bayer aims to become leaner and more efficient. We wish them luck and a steady hand in reducing the excessive bureaucracy.


    Daimler Truck from the Mercedes-Benz Group is proving robust despite challenging market conditions. While business in Europe is under pressure, strong business in North America is stabilizing the balance sheet. The forecast for 2024 remains stable, with expected sales of 460,000 to 480,000 units. The operating margin exceeds analysts' expectations. The flexible production structure in the US and Mexico mitigates potential risks from possible Trump tariffs. After 20 years of development work, dynaCERT has achieved a milestone with its Verra certification. HydraGEN diesel optimization technology promises additional revenue streams through CO₂ certificates. With Bernd Krüper as the new head of operations in Germany and a production capacity of 6,000 units per month, dynaCERT is prepared for the expected growth. The technology offers an immediately available solution for CO₂ reduction. Bayer AG is fighting on all fronts: its agriculture division is suffering from weak markets and falling demand for glyphosate, while its pharmaceutical division is facing increasing competitive pressure. The forecast for 2024 has been revised downwards. CEO Bill Anderson is pushing ahead with the reorganization of the Company, but the transformation will take time. The share price is under pressure.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.


    Der Autor

    Juliane Zielonka

    Born in Bielefeld, she studied German, English and psychology. The emergence of the Internet in the early '90s led her from university to training in graphic design and marketing communications. After years of agency work in corporate branding, she switched to publishing and learned her editorial craft at Hubert Burda Media.

    About the author



    Related comments:

    Commented by Fabian Lorenz on December 11th, 2024 | 07:45 CET

    New hydrogen hype in 2025? Nel ASA, thyssenkrupp nucera, Plug Power, and First Hydrogen

    • Hydrogen
    • greenhydrogen
    • renewableenergies

    Is nuclear-based hydrogen fueling a comeback for the industry? The growing energy demand for AI and other technologies is straining electricity grids. Shares of First Hydrogen have surged 17% following its announcement to venture into small nuclear reactors for hydrogen production, yet the Company is still valued at less than CAD 20 million. Nel is to build a pilot plant in South Korea to produce hydrogen from surplus nuclear power. However, the valuation of the Norwegian company still seems too high. Plug Power shareholders might face turbulent times in the coming weeks as short-sellers position themselves. By contrast, thyssenkrupp nucera is recommended as a "Buy". Which hydrogen player will take off in 2025?

    Read

    Commented by Stefan Feulner on December 10th, 2024 | 07:30 CET

    Novo Nordisk, BioNxt Solutions, Bayer – The market continues to boom

    • Biotechnology
    • Biotech
    • Pharma

    The weight-loss drug market was one of the fastest-growing sectors in the past year and shows no signs of slowing down in 2025. Companies like Novo Nordisk have seen their valuations multiply in recent years, significantly boosting their market capitalization. At the same time, smaller life sciences companies in the second tier, such as those with breakthrough technologies, offer interesting entry opportunities.

    Read

    Commented by André Will-Laudien on December 10th, 2024 | 07:00 CET

    Biotech Acquisitions in 2025: Several 100% Gains Expected – Evotec, Vidac Pharma, BioNTech, and Pfizer

    • Biotech
    • Pharma
    • Biotechnology

    There have already been two attempts, but the story continues! Evotec speculators were confronted with a rumor mill and a takeover bid in November. This is what happens when a stock plummets and languishes for a long time. The management wisely rejected Halozyme's undervalued offer, and thus, the bidding war for the Hamburg-based company began anew. In the biotech sector, eyes should now be on the future, as the first movements have already taken place. In our stock selection, there are three outliers with price increases of more than 30% in the last 3 months. However, the big moves will only take place in 2025. Here is an analytical look at a long-neglected sector.

    Read